EDGE Unveils First UAE-made Family of Smart Loitering Munitions at IDEX 2021
21.2.2021 19:08:00 EET | Business Wire | Press release
EDGE, an advanced technology group for defence and beyond, today launches its first family of multirotor loitering munitions, the QX range. In addition, Shadow 50 and Shadow 25, Rash 2 gliding munition kit, as well as new variants of the RW24 range – all designed and manufactured in the company’s first year of operations – were unveiled on the first day of the International Defence Exhibition and Conference (IDEX 2021), that is underway at the Abu Dhabi National Exhibition Centre until 25 February.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005030/en/
EDGE launches QX range- its first family of multirotor loitering munitions (Photo: AETOSWire)
The unveiling of the Class-1 electric unmanned aerial vehicles (UAVs) took place at the EDGE pavilion in the presence of His Excellency Faisal Al Bannai, CEO and Managing Director of EDGE and Ali Al Yafei, CEO of ADASI.
His Excellency Faisal Al Bannai, CEO & Managing Director, EDGE, said: “Right now, drone technology is revolutionising our world with the full potential of unmanned and autonomous capabilities still to be further explored – not just in the military sector, but the commercial sector too.”
He added: “Through launching the first UAE-made family of smart loitering drones, EDGE marks a significant milestone as a key technology enabler and in boosting the country’s autonomous capabilities and AI integration. With the future increasingly relying on unmanned systems that provide a higher degree of tactical flexibility, we have invested extensively to fast-track R&D investments in these domains, bringing related products to market with speed.”
The QX family of loitering munitions comprises four products: QX-1, a micro-UAV, QX-2, a mini-UAV, QX-3, a small UAV, and QX-4, which features an impressive vertical take-off and landing (VTOL) fixed wing. The precision-guided systems use sophisticated AI algorithms to target and strike, boasting an accuracy of 1 m CEP (circular error probable) – with an aim similar to laser guided munitions. Built to launch in any environment or terrain, the entire QX family of UAVs are lightweight, man portable, and comprise VTOL capabilities.
The second range of loitering munitions consists of Shadow 50 and Shadow 25. As the name implies, Shadow 50 can carry a payload of 50kg – exactly double its counterpart. Shadow 25 is a high-speed system equipped with a jet engine and boasts a short reaction time. Delivering high precision strike against fixed targets and advanced guidance capabilities, these UAVs leverage Global Navigation Satellite Systems (GNSS) and can fly using video navigation systems in GPS denied Environment.
Also launched on Day 1 of IDEX, the Rash 2 is a fixed-wing guidance kit for mortars and other in-house designed payloads, capable of gliding in flight and directing munitions to ground targets, available in different sizes to accommodate varying payload capacity, range, and endurance. ADASI has secured AED 55 million contract to supply Rash 2 to the UAE Armed Forces, marking the first order of the newly launched product.
Three new additions to the RW-24 range were also launched in time for IDEX 2021. The newly unveiled RW-24 Seeker is equipped with a thermal automatic seeker that enable greater accuracy of engagement of moving targets and increased functionality within GPS-denied environments.
The RW-24 Extended Warhead and RW-24 Extended Range variants increase the payload capacity from 8 kg to 13 kg, enabling the drone to carry additional fuel or to increase the size of the warhead.
EDGE is an advanced technology group that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005030/en/
Contact information
Thushara Mohanan
media@edgegroup.ae
+971-555080413/ +971-55-3584520
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom